Inovalon (INOV) to be acquired by Nordic Capital?

• Update: Acquired by Nordic Capital and Insight Partners for $7.3 Billion. (Aug 19, 2021) 

(Bloomberg) -- Private equity firm Nordic Capital is in advanced talks on a potential acquisition of health-care technology company Inovalon Holdings Inc., according to people familiar with the matter.

A final agreement hasn’t been reached and discussions could still fall apart, said the people, who asked not to be identified because the information was private. Representatives for Nordic Capital and Inovalon didn’t immediately respond to requests for comment outside of normal business hours.

 

 

 

 

 

 

 

Shares of Inovalon have risen about 80% this year through Monday, giving it a market value of about $5.1 billion. Inovalon jumped as much as 13% in pre-market U.S. trading Tuesday.

Inovalon, based in Bowie, Maryland, went public in 2015 in an initial public offering that raised about $685 million. The company’s software is used to aggregate and analyze health-care data from researchers and providers, according to its website.

Its database includes information from more than 1 million physicians, 580,000 clinical facilities and 336 million patients. The software is used by all of the top 25 U.S. health plans as well as the world’s top 25 pharmaceutical companies, the company said. Inovalon is scheduled to report its second-quarter earnings on July 28.

Based in Stockholm, Nordic Capital has raised more than 1.2 billion euros ($1.4 billion) for a new fund intended to invest 35 million euros to 150 million euros in health care, technology and financial services firms across northern Europe.

On Monday, it agreed to invest in Dutch outpatient health-care provider Equipe Zorgbedrijven. That followed a roughly $846 million deal in June for speciality pharmaceutical company Advanz Pharma, and the agreement in March to acquire a stake in Danish dermatology firm LEO Pharma A/S.

Private equity firms have agreed $106 billion of acquisitions in the health-care sector globally this year, according to data compiled by Bloomberg. That’s up more than 300% on the same period in 2020, the data show.

Inovalon (INOV) reported earnings on Wed 30 Oct 19 (a/h)

** charts before earnings **

 

** charts after earnings **

Inovalon beats by $0.03, reports revs in-line; guides FY20 EPS above consensus, revs above consensus

Reports Q3 (Sep) earnings of $0.15 per share, $0.03 better than the S&P Capital IQ Consensus of $0.12; revenues rose 14.2% year/year to $166.5 mln vs the $164.92 mln S&P Capital IQ Consensus.

Annual Contract Value (ACV) for new sales totaled $44.1 mln.

Reports Adjusted EBITDA of $56.3 mln, up 7% yr/yr, resulting in Adjusted EBITDA margin of 33.8%.

Co issues upside guidance for FY20, sees EPS of $0.57-$0.61 vs. $0.56 S&P Capital IQ Consensus; sees FY20 revs of $698-$718 mln vs. $697.73 mln S&P Capital IQ Consensus.

Inovalon (INOV) : 4-year performance

Inovalon (INOV) reported earnings on Tue 8 May 2018 (a/h)

• BOWIE, Md. (AP) _ Inovalon Holdings Inc. (INOV) on Tuesday reported a first-quarter loss of $16.3 million, after reporting a profit in the same period a year earlier.
** charts before earnings **







 









** charts after earnings **







 


















Inovalon misses by $0.10, misses on revs; guides FY18 EPS below consensus, reaffirms FY18 revs guidance 

• Reports Q1 (Mar) loss of $0.04 per share, excluding non-recurring items, $0.10 worse than the Capital IQ Consensus of $0.06; revenues fell 14.4% year/year to $92.76 mln vs the $107.76 mln Capital IQ Consensus.
  • Cost of revenue for the first quarter of 2018 was $33.5 million, or 36.1% of revenue, compared with $38.3 million, or 35.3% of revenue for the first quarter of 2017.
• Co issues guidance for FY18, sees EPS of $0.32-0.38, excluding non-recurring items, vs. $0.39 Capital IQ Consensus Estimate; sees FY18 revs of $568-593 mln vs. $576.37 mln Capital IQ Consensus Estimate.
  • previous EPS guidance was $0.36-0.42

Inovalon (INOV) reported earnings on Wed 2 Nov 2016 (a/h)

** charts after earnings **

  

BOWIE, Md. (AP) _ Inovalon Holdings Inc. (INOV) on Wednesday reported third-quarter earnings of $7.8 million.

On a per-share basis, the Bowie, Maryland-based company said it had profit of 5 cents.

The results did not meet Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 6 cents per share.

The health technology company posted revenue of $105 million in the period, beating Street forecasts. Four analysts surveyed by Zacks expected $100.7 million.

Inovalon Holdings expects full-year earnings in the range of 39 cents to 46 cents per share, with revenue in the range of $470 million to $490 million.

Inovalon Holdings shares have decreased 21 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $13.50, a drop of 42 percent in the last 12 months.

Inovalon (INOV) reported earnings Wed 3 Aug 2016 (a/h)

** charts after earnings **

  

• Q2 revenue miss, and FY16 EPS and revenue guidance below consensus.

Second Quarter 2016 Highlights

• Second quarter revenue of $123.8 million
• Second quarter net income of $16.3 million, resulting in diluted net income of $0.11 per share
• Second quarter Non-GAAP net income of $20.6 million, resulting in Non-GAAP diluted net income of $0.14 per share
• Second quarter Adjusted EBITDA of $40.8 million
• MORE2 Registry® dataset medical event count expanded to more than 11.7 billion
• Accelerating transition to pure cloud-based platform and adjusting 2016 financial guidance

Inovalon (INOV) reported earnings on Wed 4 Nov 2015 (a/h)

** charts 2 days after earnings **

  

• 10 days later:

Inovalon (INOV) : 4-month performance

Inovalon (INOV) began trading on the NASDAQ on 12 February 2015

Description

Inovalon Holdings, Inc. is a technology company that offers cloud-based data analytics and data-driven intervention platforms across the healthcare landscape. The Company’s data analytics platforms identify gaps in care, quality, data integrity, and financial performance in its client’s datasets. Its data-driven intervention platforms enable its clients to take the insights derived from the analytics and implement patient-level solutions, drive impact and enhance patient engagement. Its operations are divided into two groups. IT operations group manages the process steps from data receipt through to the generation of analytical outputs; services operations group manages the process steps applied to achieve impact through its data-driven intervention platforms. Its clients include health plans, hospitals, physicians, patients, pharmaceutical companies and researchers.

Address

4321 Collington Rd
BOWIE, MD 20716-2259
United States

Website 

http://www.inovalon.com

Key stats and ratios

	Q3 (Sep '14)	2013
Net profit margin	15.89%	11.06%
Operating margin	26.90%	17.73%
EBITD margin	-	22.98%
Return on average assets	17.64%	11.78%
Return on average equity	45.99%	13.97%
Employees	1,467